Stopping GLP-1 therapy doubles heart attack risk in type 2 diabetics

A study indicates that type 2 diabetes patients who discontinue GLP-1 receptor agonists like Ozempic face roughly double the risk of heart attack. The finding underscores the cardiovascular benefits of continued therapy, though causality and confounding factors remain uncertain. This matters for clinical guidelines and patient adherence.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works